Skip to main content

Table 2 Cox proportional-hazards regression: univariate and multivariate analyses of Time to Treatment Failure

From: A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

  Time to Treatment Failure
Univariate Analysis Multivariate Analysis
VARIABLE (Comparator) HR (95% CI); p - value HR (95% CI); p - value
BMI
≥ 25 vs < 25
0.51 (0.44–0.60); p < 0.0001 0.67 (0.53–0.85); p = 0.0009
Weighta 0.98 (0.97–0.99); p < 0.0001 0.99 (0.98–1.01); p = 0.8422
irAEs of any grade
Yes vs No
0.57 (0.48–0.66); p < 0.0001 0.79 (0.65–0.97); p = 0.0295
Primary Tumor (NSCLC)   
 Melanoma
 Kidney
 Others
0.62 (0.50–0.76); p < 0.0001
0.73 (0.59–0.92); p = 0.0077
1.15 (0.71–1.87); p = 0.5560
0.79 (0.64–1.01); p = 0.0517
0.71 (0.56–0.88); p = 0.0025
0.78 (0.48–1.28); p = 0.3389
Sex
Male vs Female
1.22 (1.04–1.43); p = 0.0147 1.10 (0.93–1.30); p = 0.2607
Age
Elderly vs Non-elderly
1.04 (0.90–1.21); p = 0.5366
Treatment line
Non-first vs First
1.36 (1.13–1.64); p = 0.0008 1.51 (1.25–1.81); p < 0.0001
N° of metastatic sites
> 2 vs ≤ 2
1.54 (1.34–1.77); p < 0.0001 1.52 (1.30–1.77); p < 0.0001
ECOG PS
≥2 vs 0–1
2.86 (2.36–3.48); p < 0.0001 2.35 (1.92–2.88); p < 0.0001
  1. aWeight was used as a continuous variable